肿瘤逃避免疫识别所采用的分子机制：免疫基因治疗与主要组织相容性复合体I类的细胞生物学
Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I.
作者信息
Restifo N P, Kawakami Y, Marincola F, Shamamian P, Taggarse A, Esquivel F, Rosenberg S A
机构信息
Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.
出版信息
J Immunother Emphasis Tumor Immunol. 1993 Oct;14(3):182-90. doi: 10.1097/00002371-199310000-00004.
Abstract
In this article, we explore the hypothesis that tumor cells can escape recognition by CD8+ T cells via deficiencies in antigen processing and presentation. Aspects of the molecular and cellular biology of major histocompatibility complex class I are reviewed. Evidence for histology-specific molecular mechanisms in the antigen-processing and -presentation deficiencies observed in some human and murine tumors is presented. Mechanisms identified include down-regulation of antigen processing, loss of functional beta 2-microglobulin, and deletion of specific alpha-chain alleles. Finally, we discuss studies using an antigen-presentation-deficient mouse tumor as a model for the immunogenetherapy of an antigen-presentation deficiency.
摘要
在本文中，我们探讨了肿瘤细胞可通过抗原加工和呈递缺陷逃避CD8+T细胞识别的假说。回顾了主要组织相容性复合体I类分子和细胞生物学的各个方面。展示了在一些人类和小鼠肿瘤中观察到的抗原加工和呈递缺陷中组织学特异性分子机制的证据。已确定的机制包括抗原加工下调、功能性β2微球蛋白缺失以及特定α链等位基因的缺失。最后，我们讨论了使用抗原呈递缺陷的小鼠肿瘤作为抗原呈递缺陷免疫基因治疗模型的研究。
相似文献
1
Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I.肿瘤逃避免疫识别所采用的分子机制：免疫基因治疗与主要组织相容性复合体I类的细胞生物学
J Immunother Emphasis Tumor Immunol. 1993 Oct;14(3):182-90. doi: 10.1097/00002371-199310000-00004.
2
Molecular characterization of defective antigen processing in human prostate cancer.人类前列腺癌中抗原加工缺陷的分子特征
J Natl Cancer Inst. 1995 Feb 15;87(4):280-5. doi: 10.1093/jnci/87.4.280.
3
Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.肺癌免疫治疗的最新进展：与肽加工受损相关的 T 细胞表位的作用。
Front Immunol. 2019 Jul 3;10:1505. doi: 10.3389/fimmu.2019.01505. eCollection 2019.
4
Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts.致癌转化的小鼠成纤维细胞后MHC I类抗原加工机制的下调
Eur J Immunol. 1998 Jan;28(1):122-33. doi: 10.1002/(SICI)1521-4141(199801)28:01<122::AID-IMMU122>3.0.CO;2-F.
5
Immune selection in murine tumors. Ph.d thesis.小鼠肿瘤中的免疫选择。博士论文。
APMIS Suppl. 2003(106):1-46.
6
Expression and modulation of major histocompatibility antigens on murine primary brain tumor in vitro.小鼠原发性脑肿瘤主要组织相容性抗原在体外的表达与调控
J Neurosurg. 1991 Dec;75(6):922-9. doi: 10.3171/jns.1991.75.6.0922.
7
Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC.在体内，针对低I类主要组织相容性复合体的前列腺癌，抗原特异性肿瘤疫苗的疗效需要有功能的II类主要组织相容性复合体。
Prostate. 2002 Nov 1;53(3):183-91. doi: 10.1002/pros.10136.
8
Antigen processing: where tumor-specific T-cell responses begin.
J Immunother Emphasis Tumor Immunol. 1993 Oct;14(3):202-8. doi: 10.1097/00002371-199310000-00006.
9
Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.肿瘤特异性CTL反应需要四种不同细胞类型的相互作用以及对MHC I类和II类限制性肿瘤抗原的识别。
Immunol Cell Biol. 1993 Aug;71 ( Pt 4):311-26. doi: 10.1038/icb.1993.36.
10
IFN-γ treatment protocol for MHC-I/PD-L1 pancreatic tumor cells selectively restores their TAP-mediated presentation competence and CD8 T-cell priming potential.IFN-γ 治疗方案可选择性恢复 MHC-I/PD-L1 阳性胰腺肿瘤细胞的 TAP 介导递呈能力及其 CD8+T 细胞的初始激活潜能。
J Immunother Cancer. 2020 Aug;8(2). doi: 10.1136/jitc-2020-000692.
引用本文的文献
1
The antigen-binding moiety in the driver's seat of CARs.CAR 中的抗原结合部分位于驾驶座。
Med Res Rev. 2022 Jan;42(1):306-342. doi: 10.1002/med.21818. Epub 2021 May 24.
2
Immuno-Oncotherapeutic Approaches in Advanced Hepatocellular Carcinoma.晚期肝细胞癌的免疫肿瘤治疗方法
Vaccines (Basel). 2020 Aug 8;8(3):447. doi: 10.3390/vaccines8030447.
3
Eya3 promotes breast tumor-associated immune suppression via threonine phosphatase-mediated PD-L1 upregulation.Eya3 通过丝氨酸磷酸酶介导的 PD-L1 上调促进乳腺癌相关免疫抑制。
J Clin Invest. 2018 Jun 1;128(6):2535-2550. doi: 10.1172/JCI96784. Epub 2018 May 14.
4
Identification of neoepitopes recognized by tumor-infiltrating lymphocytes (TILs) from patients with glioma.鉴定来自胶质瘤患者的肿瘤浸润淋巴细胞（TILs）所识别的新抗原表位。
Oncotarget. 2018 Apr 13;9(28):19469-19480. doi: 10.18632/oncotarget.24955.
5
Novel "Elements" of Immune Suppression within the Tumor Microenvironment.肿瘤微环境中的免疫抑制新“元素”。
Cancer Immunol Res. 2017 Jun;5(6):426-433. doi: 10.1158/2326-6066.CIR-17-0117.
6
Homologous Prime-Boost Vaccination with OVA Entrapped in Self-Adjuvanting Archaeosomes Induces High Numbers of OVA-Specific CD8⁺ T Cells that Protect Against Subcutaneous B16-OVA Melanoma.用包裹在自佐剂古脂质体中的卵清蛋白（OVA）进行同源初免-加强免疫接种可诱导产生大量OVA特异性CD8⁺ T细胞，这些细胞可抵御皮下B16-OVA黑色素瘤。
Vaccines (Basel). 2016 Nov 17;4(4):44. doi: 10.3390/vaccines4040044.
7
Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity.鼻内mRNA纳米颗粒疫苗接种可诱导预防性和治疗性抗肿瘤免疫。
Sci Rep. 2014 Jun 4;4:5128. doi: 10.1038/srep05128.
8
Killer immunoglobulin-like receptors and tumor immunity.杀伤细胞免疫球蛋白样受体与肿瘤免疫。
Cancer Immunol Res. 2014 Feb;2(2):99-104. doi: 10.1158/2326-6066.CIR-13-0219.
9
The dendritic cell-regulatory T lymphocyte crosstalk contributes to tumor-induced tolerance.树突状细胞与调节性T淋巴细胞的相互作用导致肿瘤诱导的免疫耐受。
Clin Dev Immunol. 2011;2011:430394. doi: 10.1155/2011/430394. Epub 2011 Nov 3.
10
[Natural killer cells and cancer. Regulation by the killer cell Ig-like receptors (KIR)].[自然杀伤细胞与癌症。杀伤细胞免疫球蛋白样受体（KIR）的调节作用]
Zhongguo Fei Ai Za Zhi. 2010 Jul;13(7):731-6. doi: 10.3779/j.issn.1009-3419.2010.07.14.
本文引用的文献
1
Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients.黑色素瘤细胞和正常黑素细胞具有黑色素瘤患者来源的、被HLA - A2限制性细胞毒性T细胞克隆识别的共同抗原。
J Exp Med. 1993 Apr 1;177(4):989-98. doi: 10.1084/jem.177.4.989.
2
Antimetastatic vaccination of tumor-bearing mice with two types of IFN-gamma gene-inserted tumor cells.用两种插入γ干扰素基因的肿瘤细胞对荷瘤小鼠进行抗转移疫苗接种。
J Immunol. 1993 Feb 15;150(4):1458-70.
3
Identification of human cancers deficient in antigen processing.缺乏抗原加工的人类癌症的鉴定。
J Exp Med. 1993 Feb 1;177(2):265-72. doi: 10.1084/jem.177.2.265.
4
Primary structure of human T-cell receptor alpha-chain.人T细胞受体α链的一级结构
Nature. 1984;312(5996):771-5. doi: 10.1038/312771a0.
5
A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes.一种采用肿瘤浸润淋巴细胞进行癌症过继性免疫治疗的新方法。
Science. 1986 Sep 19;233(4770):1318-21. doi: 10.1126/science.3489291.
6
Synthesis and cellular location of the ten influenza polypeptides individually expressed by recombinant vaccinia viruses.由重组痘苗病毒单独表达的十种流感病毒多肽的合成与细胞定位。
Virology. 1987 Oct;160(2):336-45. doi: 10.1016/0042-6822(87)90004-3.
7
Unique tumor-specific antigens.独特的肿瘤特异性抗原。
Annu Rev Immunol. 1988;6:465-83. doi: 10.1146/annurev.iy.06.040188.002341.
8
Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.肿瘤浸润淋巴细胞和白细胞介素-2在转移性黑色素瘤患者免疫治疗中的应用。初步报告。
N Engl J Med. 1988 Dec 22;319(25):1676-80. doi: 10.1056/NEJM198812223192527.
9
10
Association of class I major histocompatibility heavy and light chains induced by viral peptides.病毒肽诱导的I类主要组织相容性重链和轻链的关联
Nature. 1989 Aug 10;340(6233):443-8. doi: 10.1038/340443a0.
Zotero 插件